首页 > 最新文献

Neurodegenerative disease management最新文献

英文 中文
Characterizing the 'feel-good experience' in multiple sclerosis patients treated with natalizumab or other therapies. 在接受natalizumab或其他疗法治疗的多发性硬化症患者中描述“感觉良好的体验”。
IF 2.6 Q3 Medicine Pub Date : 2023-02-01 DOI: 10.2217/nmt-2022-0003
John Foley, Regina Berkovich, Mark Gudesblatt, Elizabeth Luce, Beth Schneider, Carl de Moor, Shirley Liao, Lily Lee, Karthik Bodhinathan, Robin Avila

Aim: Patients with relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab have anecdotally reported a 'feel-good experience' (FGE). The authors characterized the FGE using survey data from patients with RRMS treated with natalizumab or other disease-modifying therapies (other-DMT). Methods: Questionnaire data from RRMS patients who use MyMSTeam, an online patient social network, were analyzed. Results: The survey included 347 patients (95 natalizumab; 252 other-DMT). More natalizumab than other-DMT patients self-reported having an FGE (62.1 vs 44.8%; p = 0.001) as well as other physical, emotional and cognitive benefits. Conclusion: This study demonstrates that physical, emotional and cognitive benefits were more commonly reported by patients treated with natalizumab than those treated with other disease-modifying therapies and helps characterize patient-reported factors associated with the FGE.

目的:接受natalizumab治疗的复发-缓解型多发性硬化症(RRMS)患者有一种“感觉良好的体验”(FGE)。作者使用接受natalizumab或其他疾病改善疗法(other- dmt)治疗的RRMS患者的调查数据来描述FGE。方法:对使用在线患者社交网络MyMSTeam的RRMS患者的问卷数据进行分析。结果:调查包括347例患者(95例natalizumab;252 other-DMT)。natalizumab比其他dmt患者自我报告的FGE更多(62.1 vs 44.8%;P = 0.001),以及其他身体、情感和认知方面的益处。结论:本研究表明,接受natalizumab治疗的患者比接受其他疾病改善疗法治疗的患者更常报告身体、情绪和认知方面的益处,并有助于表征患者报告的与FGE相关的因素。
{"title":"Characterizing the 'feel-good experience' in multiple sclerosis patients treated with natalizumab or other therapies.","authors":"John Foley,&nbsp;Regina Berkovich,&nbsp;Mark Gudesblatt,&nbsp;Elizabeth Luce,&nbsp;Beth Schneider,&nbsp;Carl de Moor,&nbsp;Shirley Liao,&nbsp;Lily Lee,&nbsp;Karthik Bodhinathan,&nbsp;Robin Avila","doi":"10.2217/nmt-2022-0003","DOIUrl":"https://doi.org/10.2217/nmt-2022-0003","url":null,"abstract":"<p><p><b>Aim:</b> Patients with relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab have anecdotally reported a 'feel-good experience' (FGE). The authors characterized the FGE using survey data from patients with RRMS treated with natalizumab or other disease-modifying therapies (other-DMT). <b>Methods:</b> Questionnaire data from RRMS patients who use MyMSTeam, an online patient social network, were analyzed. <b>Results:</b> The survey included 347 patients (95 natalizumab; 252 other-DMT). More natalizumab than other-DMT patients self-reported having an FGE (62.1 vs 44.8%; p = 0.001) as well as other physical, emotional and cognitive benefits. <b>Conclusion:</b> This study demonstrates that physical, emotional and cognitive benefits were more commonly reported by patients treated with natalizumab than those treated with other disease-modifying therapies and helps characterize patient-reported factors associated with the FGE.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10797634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Welcome to Volume 13 of Neurodegenerative Disease Management. 欢迎阅读《神经退行性疾病管理》第 13 卷。
IF 2.6 Q3 Medicine Pub Date : 2023-02-01 DOI: 10.2217/nmt-2022-0042
Emily Powell
{"title":"Welcome to Volume 13 of <i>Neurodegenerative Disease Management</i>.","authors":"Emily Powell","doi":"10.2217/nmt-2022-0042","DOIUrl":"10.2217/nmt-2022-0042","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9143453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health-related quality-of-life and burden for caregivers of individuals with neurogenic orthostatic hypotension. 神经源性直立性低血压患者护理人员的健康相关生活质量和负担
IF 2.6 Q3 Medicine Pub Date : 2023-02-01 DOI: 10.2217/nmt-2022-0015
Katy Gallop, Ngan Pham, Grant Maclaine, Emma Saunders, Bonnie Black, Lena Hubig, Sarah Acaster

Aim: This study explores the burden of caring for an individual with neurogenic orthostatic hypotension (nOH) and an underlying neurodegenerative disease (Parkinson's disease, multiple system atrophy, pure autonomic failure or dementia with Lewy bodies). Materials & methods: A survey including several validated instruments was conducted with informal caregivers of individuals with Parkinson's disease, multiple system atrophy, pure autonomic failure or dementia with Lewy bodies. Results: Caregivers of patients with nOH (n = 60) reported greater burden across all outcomes compared with those without nOH (n = 60). Receiving pharmacological treatment for nOH was the variable most consistently associated with significantly better caregiver health-related quality-of-life (p < 0.05). Conclusion: This study demonstrates the burden of nOH on informal caregivers and highlights the potential benefit of pharmacological treatment not only for patients but also indirectly, their caregivers.

目的:本研究探讨神经源性直立性低血压(nOH)和潜在神经退行性疾病(帕金森病、多系统萎缩、纯自主神经衰竭或路易体痴呆)患者的护理负担。材料与方法:对帕金森病、多系统萎缩、纯自主神经衰竭或路易体痴呆患者的非正式照顾者进行了一项调查,包括几种经过验证的工具。结果:与没有nOH的患者(n = 60)相比,nOH患者(n = 60)的护理人员在所有结果中报告了更大的负担。接受药物治疗的nOH是最一致地与更好的护理者健康相关生活质量显著相关的变量(p结论:本研究表明nOH对非正式护理者的负担,并强调药物治疗不仅对患者而且间接对其护理者的潜在益处。
{"title":"Health-related quality-of-life and burden for caregivers of individuals with neurogenic orthostatic hypotension.","authors":"Katy Gallop,&nbsp;Ngan Pham,&nbsp;Grant Maclaine,&nbsp;Emma Saunders,&nbsp;Bonnie Black,&nbsp;Lena Hubig,&nbsp;Sarah Acaster","doi":"10.2217/nmt-2022-0015","DOIUrl":"https://doi.org/10.2217/nmt-2022-0015","url":null,"abstract":"<p><p><b>Aim:</b> This study explores the burden of caring for an individual with neurogenic orthostatic hypotension (nOH) and an underlying neurodegenerative disease (Parkinson's disease, multiple system atrophy, pure autonomic failure or dementia with Lewy bodies). <b>Materials & methods:</b> A survey including several validated instruments was conducted with informal caregivers of individuals with Parkinson's disease, multiple system atrophy, pure autonomic failure or dementia with Lewy bodies. <b>Results:</b> Caregivers of patients with nOH (n = 60) reported greater burden across all outcomes compared with those without nOH (n = 60). Receiving pharmacological treatment for nOH was the variable most consistently associated with significantly better caregiver health-related quality-of-life (p < 0.05). <b>Conclusion:</b> This study demonstrates the burden of nOH on informal caregivers and highlights the potential benefit of pharmacological treatment not only for patients but also indirectly, their caregivers.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10793820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary. 用克拉德滨片治疗多发性硬化症患者5年以上的疾病稳定性:简单的语言总结。
IF 2.6 Q3 Medicine Pub Date : 2022-12-01 Epub Date: 2022-08-26 DOI: 10.2217/nmt-2022-0018
Gavin Giovannoni, Giancarlo Comi, Kottil Rammohan, Peter Rieckmann, Fernando Dangond, Dominic Jack, Patrick Vermersch

What is this summary about?: This is a summary of an article originally published in the journal Advances in Therapy. Cladribine tablets are approved for treating people with relapsing multiple sclerosis (shortened to MS). People with MS take cladribine tablets for 2 periods of 4 to 5 days per year. This analysis looks at the results from 2 studies called the CLARITY and CLARITY Extension studies. These studies looked at what effect a 2-year course of treatment with cladribine tablets had on disability over 5 years in people with MS.

How was the analysis carried out?: In this analysis, researchers measured disability worsening at regular intervals during the 2-year treatment period in the CLARITY study and thereafter in the 2-year CLARITY Extension study. As many patients had a bridging interval between CLARITY and CLARITY extension, the researchers were able to assess disability over a 5-year timeframe.

What were the results?: When measurements were taken at Year 5 of the study, disability remained stable in more than half of participants. Over the 5-year period, 70% of participants did not experience persistent disease worsening that lasted more than 6 months.

What do the results mean?: Researchers concluded that a 2-year course of cladribine tablets may provide long-term benefits on disability for up to 5 years. Clinical Trial Registration: NCT00213135 (ClinicalTrials.gov) Clinical Trial Registration: NCT00641537 (ClinicalTrials.gov).

这个总结是关于什么的?这是最初发表在《治疗进展》杂志上的一篇文章的摘要。克拉德滨片被批准用于治疗复发性多发性硬化症(简称MS)。多发性硬化症患者每年服用克拉德里滨片剂2次,每次4 - 5天。该分析着眼于两项研究的结果,分别是CLARITY和CLARITY扩展研究。这些研究着眼于用克拉德滨片治疗2年对多发性硬化症患者超过5年的残疾有什么影响,分析是如何进行的?在这项分析中,研究人员在CLARITY研究的2年治疗期间和随后的2年CLARITY扩展研究中定期测量残疾恶化情况。由于许多患者在CLARITY和CLARITY扩展之间有一个桥接间隔,研究人员能够在5年的时间框架内评估残疾。结果如何?在研究的第5年进行测量时,超过一半的参与者的残疾状况保持稳定。在5年期间,70%的参与者没有经历持续6个月以上的持续疾病恶化。这些结果意味着什么?研究人员得出结论,2年疗程的克拉宾片可能对残疾患者提供长达5年的长期益处。临床试验注册:NCT00213135 (ClinicalTrials.gov)临床试验注册:NCT00641537 (ClinicalTrials.gov)。
{"title":"Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.","authors":"Gavin Giovannoni,&nbsp;Giancarlo Comi,&nbsp;Kottil Rammohan,&nbsp;Peter Rieckmann,&nbsp;Fernando Dangond,&nbsp;Dominic Jack,&nbsp;Patrick Vermersch","doi":"10.2217/nmt-2022-0018","DOIUrl":"https://doi.org/10.2217/nmt-2022-0018","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This is a summary of an article originally published in the journal <i>Advances in Therapy</i>. Cladribine tablets are approved for treating people with relapsing multiple sclerosis (shortened to MS). People with MS take cladribine tablets for 2 periods of 4 to 5 days per year. This analysis looks at the results from 2 studies called the CLARITY and CLARITY Extension studies. These studies looked at what effect a 2-year course of treatment with cladribine tablets had on disability over 5 years in people with MS.</p><p><strong>How was the analysis carried out?: </strong>In this analysis, researchers measured disability worsening at regular intervals during the 2-year treatment period in the CLARITY study and thereafter in the 2-year CLARITY Extension study. As many patients had a bridging interval between CLARITY and CLARITY extension, the researchers were able to assess disability over a 5-year timeframe.</p><p><strong>What were the results?: </strong>When measurements were taken at Year 5 of the study, disability remained stable in more than half of participants. Over the 5-year period, 70% of participants did not experience persistent disease worsening that lasted more than 6 months.</p><p><strong>What do the results mean?: </strong>Researchers concluded that a 2-year course of cladribine tablets may provide long-term benefits on disability for up to 5 years. <b>Clinical Trial Registration</b>: NCT00213135 (ClinicalTrials.gov) <b>Clinical Trial Registration</b>: NCT00641537 (ClinicalTrials.gov).</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33439153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary. 克拉德里滨片对活动性多发性硬化症患者的疗效:简明扼要。
IF 2.6 Q3 Medicine Pub Date : 2022-12-01 Epub Date: 2022-08-03 DOI: 10.2217/nmt-2022-0009
Patrick Vermersch, Andrew Galazka, Fernando Dangond, Doris Damian, Schiffon L Wong, Dominic Jack, Gerard Harty

What is this summary about?: This article summarizes the findings from a previously published article in Current Medical Research and Opinion. Cladribine tablets are an oral treatment for relapsing multiple sclerosis (shortened to MS), that are given for 4 periods of 4 to 5 days over 2 years (for a total of 20 days). In this analysis, researchers looked at the effects of taking either cladribine tablets or placebo (dummy pills) in a group of people with MS who had more active MS inflammation and had participated in a clinical study (called the CLARITY study). Some of these participants had taken prior medicines for MS.

What were the results?: Researchers found that in people with more active MS, treatment with cladribine tablets led to a lower risk of relapse and there were more people who had no relapses. People also had a lower chance of their MS worsening and had fewer new lesions in the brain. These benefits were seen regardless of whether the participants had prior treatment.

What do the results mean?: Researchers concluded that in these people with more active MS, treatment with cladribine tablets led to better outcomes over 2 years compared with treatment with placebo tablets, regardless of whether the participants had taken any prior MS treatments. Clinical Trial Registration: NCT00213135 (ClinicalTrials.gov).

这个总结是关于什么的?本文总结了先前发表在《当代医学研究与观点》上的一篇文章的研究结果。克拉德滨片是一种治疗复发性多发性硬化症(简称MS)的口服药物,在2年内(共20天)分4期服用,每期4 - 5天。在这项分析中,研究人员观察了在一组多发性硬化症患者中服用克拉德滨片或安慰剂(假药丸)的效果,这些患者有更活跃的多发性硬化症炎症,并参加了一项临床研究(称为CLARITY研究)。其中一些参与者之前服用过多发性硬化症的药物,结果如何?研究人员发现,在多发性硬化症更活跃的人群中,使用克拉德滨片治疗可降低复发风险,并且有更多的人没有复发。人们的多发性硬化症恶化的几率也更低,大脑中的新病变也更少。无论参与者之前是否接受过治疗,这些益处都是可见的。这些结果意味着什么?研究人员得出结论,在这些多发性硬化症活动性更强的患者中,无论受试者是否接受过任何多发性硬化症治疗,在2年内,与安慰剂片治疗相比,使用克拉德滨片治疗的结果更好。临床试验注册:NCT00213135 (ClinicalTrials.gov)。
{"title":"The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.","authors":"Patrick Vermersch,&nbsp;Andrew Galazka,&nbsp;Fernando Dangond,&nbsp;Doris Damian,&nbsp;Schiffon L Wong,&nbsp;Dominic Jack,&nbsp;Gerard Harty","doi":"10.2217/nmt-2022-0009","DOIUrl":"https://doi.org/10.2217/nmt-2022-0009","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This article summarizes the findings from a previously published article in <i>Current Medical Research and Opinion</i>. Cladribine tablets are an oral treatment for relapsing multiple sclerosis (shortened to MS), that are given for 4 periods of 4 to 5 days over 2 years (for a total of 20 days). In this analysis, researchers looked at the effects of taking either cladribine tablets or placebo (dummy pills) in a group of people with MS who had more active MS inflammation and had participated in a clinical study (called the CLARITY study). Some of these participants had taken prior medicines for MS.</p><p><strong>What were the results?: </strong>Researchers found that in people with more active MS, treatment with cladribine tablets led to a lower risk of relapse and there were more people who had no relapses. People also had a lower chance of their MS worsening and had fewer new lesions in the brain. These benefits were seen regardless of whether the participants had prior treatment.</p><p><strong>What do the results mean?: </strong>Researchers concluded that in these people with more active MS, treatment with cladribine tablets led to better outcomes over 2 years compared with treatment with placebo tablets, regardless of whether the participants had taken any prior MS treatments. <b>Clinical Trial Registration</b>: NCT00213135 (ClinicalTrials.gov).</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40687933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of vitamin D receptor polymorphisms with vitamin D and calcium levels in Turkish multiple sclerosis patients. 土耳其多发性硬化症患者维生素D受体多态性与维生素D和钙水平的关系
IF 2.6 Q3 Medicine Pub Date : 2022-12-01 Epub Date: 2022-07-18 DOI: 10.2217/nmt-2022-0005
Aylin Elkama, Gürdal Orhan, Bensu Karahalil

Aim: The present study was conducted to assess the impact of gene (vitamin D receptor [VDR] polymorphisms) - environment (serum vitamin D and calcium levels) interaction on multiple sclerosis (MS) risk. Materials & methods: FokI, BsmI, TaqI and ApaI genotyping were performed in 149 MS patients and 127 controls. We measured serum vitamin D and calcium levels. Results: No significant difference between VDR polymorphisms and MS risk was detected. In patients with FokI ff, BsmI Bb, TaqI Tt and ApaI AA genotypes, vitamin D levels were statistically higher. Serum calcium levels were significantly lower in patients with FokI FF, Ff, all BsmI and TaqI genotypes and ApaI AA and Aa genotypes. Conclusion: No significant association was found between VDR polymorphisms with MS risk.

目的:本研究旨在评估基因(维生素D受体[VDR]多态性)-环境(血清维生素D和钙水平)相互作用对多发性硬化症(MS)风险的影响。材料与方法:对149例MS患者和127例对照组进行FokI、BsmI、TaqI和ApaI基因分型。我们测量了血清维生素D和钙的水平。结果:VDR多态性与MS风险无显著性差异。FokI ff、BsmI Bb、TaqI Tt和ApaI AA基因型患者的维生素D水平在统计学上较高。FokI FF、FF、所有BsmI和TaqI基因型以及ApaI AA和AA基因型患者血清钙水平均显著降低。结论:VDR多态性与MS风险无显著相关性。
{"title":"Association of vitamin D receptor polymorphisms with vitamin D and calcium levels in Turkish multiple sclerosis patients.","authors":"Aylin Elkama,&nbsp;Gürdal Orhan,&nbsp;Bensu Karahalil","doi":"10.2217/nmt-2022-0005","DOIUrl":"https://doi.org/10.2217/nmt-2022-0005","url":null,"abstract":"<p><p><b>Aim:</b> The present study was conducted to assess the impact of gene (vitamin D receptor [VDR] polymorphisms) - environment (serum vitamin D and calcium levels) interaction on multiple sclerosis (MS) risk. <b>Materials & methods:</b> <i>FokI</i>, <i>BsmI</i>, <i>TaqI</i> and <i>ApaI</i> genotyping were performed in 149 MS patients and 127 controls. We measured serum vitamin D and calcium levels. <b>Results:</b> No significant difference between VDR polymorphisms and MS risk was detected. In patients with <i>FokI ff</i>, <i>BsmI Bb, TaqI Tt</i> and <i>ApaI AA</i> genotypes, vitamin D levels were statistically higher. Serum calcium levels were significantly lower in patients with <i>FokI FF</i>, <i>Ff</i>, all <i>BsmI</i> and <i>TaqI</i> genotypes and <i>ApaI AA</i> and <i>Aa</i> genotypes. <b>Conclusion:</b> No significant association was found between VDR polymorphisms with MS risk.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40625427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary. 多发性硬化症患者接受克拉德滨片治疗后复发的随访时间长达5年:简单的语言总结。
IF 2.6 Q3 Medicine Pub Date : 2022-12-01 Epub Date: 2022-08-26 DOI: 10.2217/nmt-2022-0019
Nicola De Stefano, Maria Pia Sormani, Gavin Giovannoni, Kottil Rammohan, Thomas P Leist, Patricia K Coyle, Fernando Dangond, Nektaria Alexandri, Andrew Galazka

What is this summary about?: This is a summary of an article originally published in the Multiple Sclerosis Journal. The article presents the results from the CLARITY and CLARITY Extension studies, which looked at how well cladribine tablets work in treating people with multiple sclerosis (shortened to MS). Cladribine tablets are a medication approved for treating relapsing forms of MS. This study looked at how treatment with cladribine tablets affects the frequency and severity of relapses in people with MS. A relapse is when new symptoms develop or old symptoms return or get worse after a period of stability or improvement.

What happened in the studies?: In the CLARITY study, 870 people received either cladribine tablets (3.5 mg/kg, the approved dose) or placebo (a dummy pill). After the CLARITY study ended, some participants who received cladribine tablets chose to take part in a second study called the CLARITY Extension study. Of these participants, 98 were given placebo for 2 more years following an interval period of up to 10 months between participating in each study.

What were the results?: People with MS who were treated with cladribine tablets for 2 years in the CLARITY study had lower risks of any relapse compared with those given placebo. Participants taking placebo (after cladribine tablets) in the CLARITY Extension study experienced these same benefits, which continued for up to 3 more years after having received cladribine tablets in the CLARITY study.

What do the results mean?: Researchers concluded the recommended 2-year dosing of cladribine tablets may reduce the number and severity of relapses in people with MS for up to 5 years. Clinical Trial Registration: NCT00213135 (ClinicalTrials.gov) Clinical Trial Registration: NCT00641537 (ClinicalTrials.gov).

这个总结是关于什么的?这是最初发表在《多发性硬化症杂志》上的一篇文章的摘要。这篇文章介绍了CLARITY和CLARITY Extension研究的结果,研究了克拉德里滨片治疗多发性硬化症(简称MS)的效果。克拉德滨是一种被批准用于治疗复发型多发性硬化症的药物。这项研究着眼于克拉德滨治疗如何影响多发性硬化症患者复发的频率和严重程度。复发是指在一段时间的稳定或改善后出现新症状或旧症状复发或恶化。研究中发生了什么?在CLARITY研究中,870人接受了克拉德里滨片剂(3.5 mg/kg,批准剂量)或安慰剂(一种假药丸)。CLARITY研究结束后,一些接受克拉德里滨片剂的参与者选择参加第二项名为CLARITY扩展研究的研究。在这些参与者中,98人在每项研究之间间隔10个月后再服用安慰剂2年。结果如何?在CLARITY研究中,接受克拉德里滨片剂治疗2年的多发性硬化症患者与接受安慰剂治疗的患者相比,复发的风险较低。在CLARITY扩展研究中,服用安慰剂(在服用克拉德里滨片之后)的参与者也经历了同样的益处,在CLARITY研究中服用克拉德里滨片后,这种益处持续了3年。这些结果意味着什么?研究人员得出结论,推荐的2年剂量的克拉德滨片可以减少多发性硬化症患者复发的次数和严重程度,最多可达5年。临床试验注册:NCT00213135 (ClinicalTrials.gov)临床试验注册:NCT00641537 (ClinicalTrials.gov)。
{"title":"Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.","authors":"Nicola De Stefano,&nbsp;Maria Pia Sormani,&nbsp;Gavin Giovannoni,&nbsp;Kottil Rammohan,&nbsp;Thomas P Leist,&nbsp;Patricia K Coyle,&nbsp;Fernando Dangond,&nbsp;Nektaria Alexandri,&nbsp;Andrew Galazka","doi":"10.2217/nmt-2022-0019","DOIUrl":"https://doi.org/10.2217/nmt-2022-0019","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This is a summary of an article originally published in the <i>Multiple Sclerosis Journal</i>. The article presents the results from the CLARITY and CLARITY Extension studies, which looked at how well cladribine tablets work in treating people with multiple sclerosis (shortened to MS). Cladribine tablets are a medication approved for treating relapsing forms of MS. This study looked at how treatment with cladribine tablets affects the frequency and severity of relapses in people with MS. A relapse is when new symptoms develop or old symptoms return or get worse after a period of stability or improvement.</p><p><strong>What happened in the studies?: </strong>In the CLARITY study, 870 people received either cladribine tablets (3.5 mg/kg, the approved dose) or placebo (a dummy pill). After the CLARITY study ended, some participants who received cladribine tablets chose to take part in a second study called the CLARITY Extension study. Of these participants, 98 were given placebo for 2 more years following an interval period of up to 10 months between participating in each study.</p><p><strong>What were the results?: </strong>People with MS who were treated with cladribine tablets for 2 years in the CLARITY study had lower risks of any relapse compared with those given placebo. Participants taking placebo (after cladribine tablets) in the CLARITY Extension study experienced these same benefits, which continued for up to 3 more years after having received cladribine tablets in the CLARITY study.</p><p><strong>What do the results mean?: </strong>Researchers concluded the recommended 2-year dosing of cladribine tablets may reduce the number and severity of relapses in people with MS for up to 5 years. <b>Clinical Trial Registration</b>: NCT00213135 (ClinicalTrials.gov) <b>Clinical Trial Registration</b>: NCT00641537 (ClinicalTrials.gov).</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33438207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality of life in people with multiple sclerosis receiving glatiramer acetate or interferon in Greek clinical practice. 希腊临床实践中接受醋酸格拉替默或干扰素治疗的多发性硬化症患者的生活质量
IF 2.6 Q3 Medicine Pub Date : 2022-12-01 Epub Date: 2022-09-30 DOI: 10.2217/nmt-2022-0004
Dimos Mitsikostas, Christos Bakirtzis, Ioannis Nikolaidis, Vana Tsimourtou, Persa Kountra, Stavroula Matsi, Alexandros Papadimitriou

Aim: To evaluate glatiramer acetate (GA) or IFN-β effects on quality of life (QoL) in people with relapsing/remitting multiple sclerosis (PwRRMS) in Greece. Methods: A prospective, practice-based study. QoL/function/symptoms were assessed by seven questionnaires/scales. Results: Significant increases in Short Form-36 (SF-36) health survey scores occurred with GA in four of the eight domains and three of the eight domains at 6 and 12 months, respectively, versus baseline. Similar and significant SF-36 score improvements occurred with GA in treatment-naive PwRRMS. SF-36 scores were unaffected in GA-treated, IFN-β treatment-experienced PwRRMS, or with IFN-β versus baseline. Slight improvements in fatigue and sexual satisfaction were evident (6 months). No deteriorations were seen in the other four instruments. Conclusion: The findings show that 12-month treatment with GA, but not IFN-β, improved certain QoL parameters in treatment-naive PwRRMS.

目的:评价醋酸格拉替默(GA)或IFN-β对希腊复发/缓解型多发性硬化症(PwRRMS)患者生活质量(QoL)的影响。方法:前瞻性、实践性研究。通过7份问卷/量表评估生活质量/功能/症状。结果:与基线相比,GA在6个月和12个月时分别在8个领域中的4个和8个领域中的3个领域中出现了短表36 (SF-36)健康调查得分的显著增加。GA在治疗初期PwRRMS中也出现了类似且显著的SF-36评分改善。SF-36评分在ga治疗、IFN-β治疗经历的PwRRMS或IFN-β治疗与基线相比未受影响。疲劳和性满意度略有改善(6个月)。其他四种仪器未见恶化。结论:GA治疗12个月,而IFN-β治疗未改善PwRRMS患者的某些生活质量参数。
{"title":"Quality of life in people with multiple sclerosis receiving glatiramer acetate or interferon in Greek clinical practice.","authors":"Dimos Mitsikostas,&nbsp;Christos Bakirtzis,&nbsp;Ioannis Nikolaidis,&nbsp;Vana Tsimourtou,&nbsp;Persa Kountra,&nbsp;Stavroula Matsi,&nbsp;Alexandros Papadimitriou","doi":"10.2217/nmt-2022-0004","DOIUrl":"https://doi.org/10.2217/nmt-2022-0004","url":null,"abstract":"<p><p><b>Aim:</b> To evaluate glatiramer acetate (GA) or IFN-β effects on quality of life (QoL) in people with relapsing/remitting multiple sclerosis (PwRRMS) in Greece. <b>Methods:</b> A prospective, practice-based study. QoL/function/symptoms were assessed by seven questionnaires/scales. <b>Results:</b> Significant increases in Short Form-36 (SF-36) health survey scores occurred with GA in four of the eight domains and three of the eight domains at 6 and 12 months, respectively, versus baseline. Similar and significant SF-36 score improvements occurred with GA in treatment-naive PwRRMS. SF-36 scores were unaffected in GA-treated, IFN-β treatment-experienced PwRRMS, or with IFN-β versus baseline. Slight improvements in fatigue and sexual satisfaction were evident (6 months). No deteriorations were seen in the other four instruments. <b>Conclusion:</b> The findings show that 12-month treatment with GA, but not IFN-β, improved certain QoL parameters in treatment-naive PwRRMS.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40386668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The use of lumbar puncture and safety recommendations in Alzheimer's disease: a plain language summary. 在阿尔茨海默病中腰椎穿刺的使用和安全性建议:一个简单的语言总结。
IF 2.6 Q3 Medicine Pub Date : 2022-10-01 Epub Date: 2022-07-22 DOI: 10.2217/nmt-2022-0012
Harald Hampel, Aya Elhage, Leslie M Shaw, Paul Aisen, Christopher Chen, Alberto Lleó, Takeshi Iwatsubo, Atsushi Iwata, Masahito Yamada, Takeshi Ikeuchi, Jianping Jia, Huali Wang, Charlotte E Teunissen, Elaine Peskind, Kaj Blennow, Jeffrey Cummings, Andrea Vergallo

What is this summary about?: This is a plain language summary of an article published in Alzheimer's & Dementia. It looks at a type of test called a lumbar puncture (also known as spinal tap) used in people suspected of having Alzheimer's disease or some other form of dementia. This summary focuses on how to do a lumbar puncture safely.

Why is this important?: Alzheimer's disease is a progressive condition, which means it gets worse over time. This leads to difficulties with thinking and memory. People with Alzheimer's disease show a build up of proteins called amyloid-β and tau in the brain. This is followed by a gradual loss of brain cells and brain function. The changes in the brain are thought to occur years before symptoms appear. Lumbar puncture is a medical procedure during which samples of cerebrospinal fluid are collected. In Alzheimer's disease, it is used to examine cerebrospinal fluid biomarkers that can help diagnose disease. Lumbar puncture is traditionally considered as a painful and invasive procedure with frequent side effects. However, multiple studies indicate that a lumbar puncture can be performed safely. Side effects are typically mild and do not require specialist intervention.

What are the key takeaways?: Despite the low risk of serious complications associated with a lumbar puncture, physicians and their patients may be reluctant to recommend or undergo this procedure. Patient education, specialist training, as well as new methods concerning patient safety are important factors to support the widespread use of lumbar puncture in Alzheimer's disease.

这个总结是关于什么的?这是发表在《阿尔茨海默病与痴呆症》杂志上的一篇文章的简明扼要的总结。它着眼于一种被称为腰椎穿刺(也称为脊髓穿刺)的测试,这种测试用于怀疑患有阿尔茨海默病或其他形式的痴呆症的人。这篇总结的重点是如何安全地做腰椎穿刺。为什么这很重要?阿尔茨海默病是一种进行性疾病,这意味着它会随着时间的推移而恶化。这会导致思考和记忆方面的困难。患有阿尔茨海默病的人大脑中淀粉样蛋白-β和tau蛋白的含量增加。随之而来的是脑细胞和大脑功能的逐渐丧失。大脑的变化被认为在症状出现前几年就发生了。腰椎穿刺是一种收集脑脊液样本的医疗程序。在阿尔茨海默病中,它被用来检查脑脊液生物标志物,帮助诊断疾病。腰椎穿刺传统上被认为是一种痛苦和侵入性的手术,而且经常有副作用。然而,多项研究表明,腰椎穿刺可以安全进行。副作用通常是轻微的,不需要专家干预。关键的收获是什么?尽管与腰椎穿刺相关的严重并发症的风险很低,但医生和他们的患者可能不愿意推荐或接受这种手术。患者教育、专家培训以及有关患者安全的新方法是支持腰椎穿刺在阿尔茨海默病中广泛应用的重要因素。
{"title":"The use of lumbar puncture and safety recommendations in Alzheimer's disease: a plain language summary.","authors":"Harald Hampel,&nbsp;Aya Elhage,&nbsp;Leslie M Shaw,&nbsp;Paul Aisen,&nbsp;Christopher Chen,&nbsp;Alberto Lleó,&nbsp;Takeshi Iwatsubo,&nbsp;Atsushi Iwata,&nbsp;Masahito Yamada,&nbsp;Takeshi Ikeuchi,&nbsp;Jianping Jia,&nbsp;Huali Wang,&nbsp;Charlotte E Teunissen,&nbsp;Elaine Peskind,&nbsp;Kaj Blennow,&nbsp;Jeffrey Cummings,&nbsp;Andrea Vergallo","doi":"10.2217/nmt-2022-0012","DOIUrl":"https://doi.org/10.2217/nmt-2022-0012","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This is a plain language summary of an article published in <i>Alzheimer's & Dementia</i>. It looks at a type of test called a lumbar puncture (also known as spinal tap) used in people suspected of having Alzheimer's disease or some other form of dementia. This summary focuses on how to do a lumbar puncture safely.</p><p><strong>Why is this important?: </strong>Alzheimer's disease is a progressive condition, which means it gets worse over time. This leads to difficulties with thinking and memory. People with Alzheimer's disease show a build up of proteins called amyloid-β and tau in the brain. This is followed by a gradual loss of brain cells and brain function. The changes in the brain are thought to occur years before symptoms appear. Lumbar puncture is a medical procedure during which samples of cerebrospinal fluid are collected. In Alzheimer's disease, it is used to examine cerebrospinal fluid biomarkers that can help diagnose disease. Lumbar puncture is traditionally considered as a painful and invasive procedure with frequent side effects. However, multiple studies indicate that a lumbar puncture can be performed safely. Side effects are typically mild and do not require specialist intervention.</p><p><strong>What are the key takeaways?: </strong>Despite the low risk of serious complications associated with a lumbar puncture, physicians and their patients may be reluctant to recommend or undergo this procedure. Patient education, specialist training, as well as new methods concerning patient safety are important factors to support the widespread use of lumbar puncture in Alzheimer's disease.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40545160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Friedreich ataxia: clinical features and new developments. 弗里德里希共济失调:临床特点和新进展。
IF 2.6 Q3 Medicine Pub Date : 2022-10-01 Epub Date: 2022-06-29 DOI: 10.2217/nmt-2022-0011
Medina Keita, Kellie McIntyre, Layne N Rodden, Kim Schadt, David R Lynch

Friedreich's ataxia (FRDA), a neurodegenerative disease characterized by ataxia and other neurological features, affects 1 in 50,000-100,000 individuals in the USA. However, FRDA also includes cardiac, orthopedic and endocrine dysfunction, giving rise to many secondary disease characteristics. The multifaceted approach for clinical care has necessitated the development of disease-specific clinical care guidelines. New developments in FRDA include the advancement of clinical drug trials targeting the NRF2 pathway and frataxin restoration. Additionally, a novel understanding of gene silencing in FRDA, reflecting a variegated silencing pattern, will have applications to current and future therapeutic interventions. Finally, new perspectives on the neuroanatomy of FRDA and its developmental features will refine the time course and anatomical targeting of novel approaches.

弗里德里希共济失调(FRDA)是一种以共济失调和其他神经系统特征为特征的神经退行性疾病,在美国,每5-10万人中就有1人患有这种疾病。然而,FRDA还包括心脏、骨科和内分泌功能障碍,从而产生许多继发性疾病特征。临床护理的多方面方法使得制定针对特定疾病的临床护理指南成为必要。FRDA的新进展包括靶向NRF2途径和frataxin修复的临床药物试验的进展。此外,对FRDA中基因沉默的新理解,反映了一种多样化的沉默模式,将在当前和未来的治疗干预中得到应用。最后,对FRDA的神经解剖学及其发育特征的新观点将完善新方法的时间进程和解剖学靶向。
{"title":"Friedreich ataxia: clinical features and new developments.","authors":"Medina Keita,&nbsp;Kellie McIntyre,&nbsp;Layne N Rodden,&nbsp;Kim Schadt,&nbsp;David R Lynch","doi":"10.2217/nmt-2022-0011","DOIUrl":"10.2217/nmt-2022-0011","url":null,"abstract":"<p><p>Friedreich's ataxia (FRDA), a neurodegenerative disease characterized by ataxia and other neurological features, affects 1 in 50,000-100,000 individuals in the USA. However, FRDA also includes cardiac, orthopedic and endocrine dysfunction, giving rise to many secondary disease characteristics. The multifaceted approach for clinical care has necessitated the development of disease-specific clinical care guidelines. New developments in FRDA include the advancement of clinical drug trials targeting the NRF2 pathway and frataxin restoration. Additionally, a novel understanding of gene silencing in FRDA, reflecting a variegated silencing pattern, will have applications to current and future therapeutic interventions. Finally, new perspectives on the neuroanatomy of FRDA and its developmental features will refine the time course and anatomical targeting of novel approaches.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9517959/pdf/nmt-12-267.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40408649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
期刊
Neurodegenerative disease management
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1